SCHEMBL787848

SCHEMBL787848

O=C(O)c1scc(Cl)c1Cl

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR35 Q9HC97 2/20 0.47
MCL1 Q07820 4/20 0.40
DAO P14920 2/20 0.40
MAPK1 P28482 1/20 0.40
KMT2A Q03164 2/20 0.39
POLB P06746 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
DPP4 P27487 1/20 0.37
BCKDK O14874 2/20 0.36
RXFP1 Q9HBX9 1/20 0.36
PTPRC P08575 1/20 0.36
PTPRG P23470 1/20 0.36
TSHR P16473 1/20 0.35
MEN1 O00255 1/20 0.35
KDM4E B2RXH2 1/20 0.34
PKM P14618 1/20 0.34
BCL2L1 Q07817 1/20 0.34
ALDH1A1 P00352 1/20 0.33
ALAD P13716 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7044916 0.82 GPR35 (0.36) GPR35MCL1DAOMAPK1KMT2A
SCHEMBL31078546 0.79 DPP4 (0.45) GPR35MCL1DAOMAPK1KMT2A
SCHEMBL27504482 0.79 GPR35 (0.60) GPR35MCL1DAOMAPK1KMT2A
SCHEMBL11602617 0.79 RAB9A (0.36) GPR35KMT2APOLBTDP1L3MBTL1
SCHEMBL7369450 0.79 GSK3B (0.39) GPR35DAOMAPK1KMT2ARXFP1
SCHEMBL18701570 0.79 GPR35 (0.46) GPR35MCL1DAOMAPK1KMT2A
SCHEMBL18701734 0.77 DAO (0.42) GPR35MCL1DAOMAPK1KMT2A
SCHEMBL10514890 0.77 GPR35 (0.44) GPR35MCL1DAOKMT2APOLB
SCHEMBL7030961 0.77 ALDH1A1 (0.46) GPR35MCL1DAOMAPK1KMT2A
SCHEMBL3636522 0.77 L3MBTL1 (0.52) GPR35MCL1DAOKMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2616466-A2 PROCESS FOR DETERMINING THE SUITABILITY FOR DISTRIBUTION OF A BATCH OF A THIOPHENE-2-CARBOXAMIDE DERIVATIVE Medichem, S.A. (ES) 2013-07-24 EP claimed
WO-2012035057-A2 PROCESS FOR DETERMINING THE SUITABILITY FOR DISTRIBUTION OF A BATCH OF A THIOPHENE-2-CARBOXAMIDE DERIVATIVE MEDICHEM S.A. (ES) 2012-03-22 WO claimed
US-11269251-B2 Resist composition and patterning process SHIN-ETSU CHEMICAL CO., LTD. (JP) 2022-03-08 US disclosed
US-20190113844-A1 RESIST COMPOSITION AND PATTERNING PROCESS SHIN-ETSU CHEMICAL CO., LTD. (JP) 2019-04-18 US disclosed
US-20180282605-A1 METHOD OF MONITORING A PARAMETER OF A HYDROCARBON WELL, PIPELINE OR FORMATION JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) 2018-10-04 US disclosed
WO-2017060699-A1 METHOD OF MONITORING A PARAMETER OF A HYDROCARBON WELL, PIPELINE OR FORMATION JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) 2017-04-13 WO disclosed
US-20130253187-A1 Process for Determining the Suitability for Distribution of a Batch of Thiophene-2-Carboxamide Derivative MEDICHEM, S.A. (ES) 2013-09-26 US disclosed
EP-2616466-A2 PROCESS FOR DETERMINING THE SUITABILITY FOR DISTRIBUTION OF A BATCH OF A THIOPHENE-2-CARBOXAMIDE DERIVATIVE Medichem, S.A. (ES) 2013-07-24 EP disclosed
WO-2012035057-A2 PROCESS FOR DETERMINING THE SUITABILITY FOR DISTRIBUTION OF A BATCH OF A THIOPHENE-2-CARBOXAMIDE DERIVATIVE MEDICHEM S.A. (ES) 2012-03-22 WO disclosed
CN-1266126-C Phenylethanolamine derivatives for the treatment of respiratory diseases GLAXO GROUP LTD (GB) 2006-07-26 CN disclosed
CN-1501911-A Phenethanolamine derivatives for treatment of respiratory diseases 2004-06-02 CN disclosed
US-6380218-B1 FOR THERAPY OF RESPIRATORY, ALLERGIC, AND INFLAMMATORY DISORDERS COMPRISING ASTHMA, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, ACUTE RESPIRATORY DISEASE SYNDROME, PULMONARY HYPERSENSITIVITY, AND ALLERGIC RHINITIS IN A MAMMAL PFIZER INC 2002-04-30 US disclosed
EP-0971894-A1 NICOTINAMIDE DERIVATIVES Pfizer Products Inc. (US) 2000-01-19 EP disclosed
WO-1998045268-A1 NICOTINAMIDE DERIVATIVES PFIZER PRODUCTS INC. (US) 1998-10-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130253187-A1 Process for Determining the Suitability for Distribution of a Batch of Thiophene-2-Carboxamide Derivative CYP2C9, CYP3A5, CYP3A43 GPR35 3497/4885MCL1 3321/4885DAO 2775/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.